Stockscreener 앱 받기
6.51
2.36%
0.15
시간 외 거래:
6.52
0.010
+0.15%
전일 마감가:
$6.36
열려 있는:
$6.35
하루 거래량:
1.45M
Relative Volume:
0.65
시가총액:
$662.39M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-22.45
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
+3.50%
1개월 성능:
+3.17%
6개월 성능:
+126.04%
1년 성능:
+151.35%
1일 변동 폭
$6.20
$6.60
1주일 범위
$6.08
$6.60
52주 변동 폭
$2.30
$7.39
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.51 | 639.97M | 0 | -29.07M | -31.85M | -0.29 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
What is HC Wainwright’s Forecast for TRVI Q2 Earnings? - Defense World
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating - MSN
Trevi Therapeutics to Participate in Upcoming June Conferences - Citizen Tribune
Trevi Therapeutics to Participate in Upcoming June Conferences | TRVI Stock News - GuruFocus
Trevi Therapeutics Reveals New Haduvio Data: Key Updates Coming at Major Medical Conferences - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright sets $21 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $21 target for Trevi Therapeutics stock - Investing.com
HC Wainwright & Co. Initiates Coverage on Trevi Therapeutics (TRVI) with Buy Rating | TRVI Stock News - GuruFocus
H.C. Wainwright Commences Coverage on Trevi Therapeutics (TRVI) with Positive Outlook | TRVI Stock News - GuruFocus
Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from Needham & Company LLC - Defense World
Raymond James sets $29 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $2 - GuruFocus
Stifel maintains Buy on Trevi Therapeutics, $15 target By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $24 Price Target | TRVI Stock News - GuruFocus
Trevi Therapeutics, Inc. Announces Additional Analyses from Phase 2A River Trial of Haduvio in Patients with Refractory Chronic Cough - marketscreener.com
Trevi Therapeutics Announces Additional Analyses from Phase 2a R - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIV - GuruFocus
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIVER Trial | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough - marketscreener.com
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PR Newswire
Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Price T Rowe Associates Inc. MD Has $104,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Raymond James Financial Inc. - Defense World
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? - Yahoo Finance
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo & Company MN Buys 9,562 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations By Investing.com - Investing.com UK
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances - GuruFocus
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
3.74%
자본화:
|
볼륨(24시간):